Showing 8 posts of 8 posts found.


AZ licenses kidney drug from Ionis for $330m

February 21, 2018
Research and Development, Sales and Marketing AstraZeneca, Ionis, Isis, biotech, drugs, kidney, pharma, pharmaceutical

AstraZeneca continues to build on its relationship with San Diego-based Ionis Pharmaceuticals, this time by agreeing a licensing deal for …


Bayer buys blood-thinning drug from Isis

May 5, 2015
Research and Development, Sales and Marketing Bayer, Eliquis, ISIS-FXI, Isis, Xarelto, blooding thinning

German drug giant Bayer is sealing a $155 million deal with Isis Pharmaceuticals to gain access to its anti-clotting treatment …

Janssen image

J&J acquires Index Ventures-owned firm XO1

March 23, 2015
Sales and Marketing Index Ventures, Isis, J&J, JJ, Janssen, vectura, xo1

Johnson & Johnson’s pharma unit Janssen has acquired Index Ventures’ biopharma firm XO1 Limited that develops the promising anti-thrombin antibody …

Janssen image

Isis and J&J sign RNA deal

January 8, 2015
Research and Development, Sales and Marketing Isis, J&J, JJ, Janssen, RNA, gastrointestinal tract

Isis Pharmaceuticals is collaborating with Johnson & Johnson’s pharma unit Janssen to develop antisense drugs to treat autoimmune disorders. The …

biogen idec image

Biogen signs neurology deal

September 11, 2013
Research and Development, Sales and Marketing Biogen IDEC, Isis, antisense, neurology

Biogen Idec and Isis Pharmaceuticals have entered their fourth partnership in two years in a deal that will see the …


Roche signs Huntington’s deal

April 10, 2013
Research and Development, Sales and Marketing Huntington's, Isis, Roche

Roche is to pay California-based Isis Pharmaceuticals $30 million upfront to cement a new alliance in which the firms will …

Pharma manufacturing news in brief

August 14, 2012
Manufacturing and Production Advanced Bioscience, Almac, Amneal, Cipla, Isis, Sanofi Pasteur

Cipla opening three new API plants as Indian trade delegations forges closer ties with Sri Lanka; plus facility updates from …

GSK signs RNA therapeutics alliance

March 31, 2010
Research and Development GlaxoSmithKline, Isis, RNA

GlaxoSmithKline has forged a new strategic alliance with Isis Pharmaceuticals to exploit the specialist company’s expertise in anti-RNA therapeutics. California-based …

Latest content